- Home
- PCLA vs COEP Comparison
PCLA vs COEP Comparison
Compare PCLA & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCLA
- COEP
- Stock Information
- Founded
- PCLA 2008
- COEP 2017
- Country
- PCLA Japan
- COEP United States
- Employees
- PCLA N/A
- COEP N/A
- Industry
- PCLA Building Products
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCLA Consumer Discretionary
- COEP Health Care
- Exchange
- PCLA Nasdaq
- COEP Nasdaq
- Market Cap
- PCLA 71.3M
- COEP 27.4M
- IPO Year
- PCLA 2025
- COEP N/A
- Fundamental
- Price
- PCLA $0.65
- COEP $9.74
- Analyst Decision
- PCLA
- COEP
- Analyst Count
- PCLA 0
- COEP 0
- Target Price
- PCLA N/A
- COEP N/A
- AVG Volume (30 Days)
- PCLA 3.2M
- COEP 37.8K
- Earning Date
- PCLA 01-01-0001
- COEP 08-15-2025
- Dividend Yield
- PCLA N/A
- COEP N/A
- EPS Growth
- PCLA N/A
- COEP N/A
- EPS
- PCLA N/A
- COEP N/A
- Revenue
- PCLA $5,475,228.00
- COEP $62,874.00
- Revenue This Year
- PCLA N/A
- COEP N/A
- Revenue Next Year
- PCLA N/A
- COEP N/A
- P/E Ratio
- PCLA N/A
- COEP N/A
- Revenue Growth
- PCLA 40.19
- COEP N/A
- 52 Week Low
- PCLA $0.37
- COEP $2.31
- 52 Week High
- PCLA $9.80
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- PCLA N/A
- COEP 59.36
- Support Level
- PCLA N/A
- COEP $7.25
- Resistance Level
- PCLA N/A
- COEP $10.00
- Average True Range (ATR)
- PCLA 0.00
- COEP 0.55
- MACD
- PCLA 0.00
- COEP 0.27
- Stochastic Oscillator
- PCLA 0.00
- COEP 81.00
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.